<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04537143</url>
  </required_header>
  <id_info>
    <org_study_id>Narcisa</org_study_id>
    <nct_id>NCT04537143</nct_id>
  </id_info>
  <brief_title>Image Biomarkers for Progression of AMD</brief_title>
  <acronym>IBPAMD</acronym>
  <official_title>Understanding Imaging Biomarkers That Predict the Progression of Age-Related Macular Degeneration on Multi-modal Novel Retinal Technologies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Doheny Image Reading Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Doheny Image Reading Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study qualitatively and quantitatively the Imaging Biomarkers (IBs) on Multi-modal Imaging&#xD;
      with Novel technologies (MINT), in order to understand their role in prediction of the&#xD;
      Age-related Macular Degeneration (AMD) progression in eyes with and without treatment. The&#xD;
      understanding of IBs will allow early detection of AMD, prediction of its evolution, and&#xD;
      guidance for the best options for stratified/individualized treatment of AMD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The qualitative studies will explore use of OCT Angiography (OCTA), Swept Source OCT&#xD;
      (SS-OCT), Ultra-Wide Field Fluorescein Angiography (UWF-FA), Adaptive Optic Scanning Laser&#xD;
      Ophthalmoscopy (AO-SLO), Fluorescence Lifetime Imaging Ophthalmoscopy (FLIO), Retro Mode&#xD;
      Imaging (RMI) and other novel technologies for the retinal diagnosis. Morphologic qualitative&#xD;
      IBs described in the literature like macular neovascularization pattern, retinal tubulations,&#xD;
      choriocapillary preservation, retinal pigment epithelium atrophy, drusen patterns, etc as&#xD;
      well as other IBPAMD original IBs classified in morphopathogenic categories like IBs&#xD;
      related-to-MNV, IBs related-to-atrophy, IBs related-to macular chorio-retinal architecture,&#xD;
      etc are analyzed in granular fashion by multi-modal imaging approach before and after&#xD;
      different treatments for AMD.&#xD;
&#xD;
      The quantitative IBs assessment will be done in dual mode - classic and original to the&#xD;
      IBPAMD trial. The lesions are quantitatively assessed on one hand, by using the classic&#xD;
      measurements of the greatest diameter, total lesions area, vessels density, fractal&#xD;
      dimension, etc, based on the classic concept of measurements expressed in absolute values&#xD;
      (mm, mm2 or pixels). The same lesions are quantitatively assessed by using the original&#xD;
      IBPAMD algorithm and software (SITE-app) that introduce a new concept in the quantification&#xD;
      of the retinal lesions, the assessment of differences reported to the baseline.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Funding for staff no longer available&#xD;
  </why_stopped>
  <start_date type="Anticipated">January 2021</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>ONH diameter</measure>
    <time_frame>1-2 year FU</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>area of MNV</measure>
    <time_frame>1-2 year FU</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>AMD</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Non-AMD eyes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AMD</arm_group_label>
    <description>AMD eyes</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Half control, half AMD eyes&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  being male or female&#xD;
&#xD;
          -  at least 18 years of age&#xD;
&#xD;
          -  varied ethnic backgrounds (different ethnic groups have different structures of eye&#xD;
             anatomy and we must be able to make ethnic subgroups to account for these differences)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  vulnerable patients&#xD;
&#xD;
          -  patients under 18&#xD;
&#xD;
          -  pregnant (we exclude pregnant women because pregnancy often can alter eye anatomy)&#xD;
&#xD;
          -  economically and educationally disadvantaged&#xD;
&#xD;
          -  decision impaired&#xD;
&#xD;
          -  homeless people.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>August 28, 2020</study_first_submitted>
  <study_first_submitted_qc>August 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 3, 2020</study_first_posted>
  <last_update_submitted>September 24, 2020</last_update_submitted>
  <last_update_submitted_qc>September 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Doheny Image Reading Center</investigator_affiliation>
    <investigator_full_name>Kenneth Marion</investigator_full_name>
    <investigator_title>Program Manager - Research</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease Progression</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

